A citation-based method for searching scientific literature

Kyung Wan Min, Bon Jeong Ku, Ji Hyun Lee, Min Seon Kim, Kyu Jeung Ahn, Moon Kyu Lee, Satoshi Kokubo, Satoshi Yoshida, Hyun Ji Cho, Bong Soo Cha. Diabetes Metab J 2017
Times Cited: 12







List of co-cited articles
116 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
58



Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016
109
41

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
41

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
J P H Wilding, E Ferrannini, V A Fonseca, W Wilpshaar, P Dhanjal, A Houzer. Diabetes Obes Metab 2013
92
41


Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.
Nisa M Maruthur, Eva Tseng, Susan Hutfless, Lisa M Wilson, Catalina Suarez-Cuervo, Zackary Berger, Yue Chu, Emmanuel Iyoha, Jodi B Segal, Shari Bolen. Ann Intern Med 2016
289
33

Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.
E S Mearns, W J Saulsberry, C M White, C G Kohn, S Lemieux, A Sihabout, I Salamucha, C I Coleman. Diabet Med 2015
32
33


Current status of managing diabetes mellitus in Korea.
Kyoung Hwa Ha, Dae Jung Kim. Korean J Intern Med 2016
23
33


Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi,[...]. Diabetes Metab J 2016
9
44

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Kun-Ho Yoon, Rimei Nishimura, Jisoo Lee, Susanne Crowe, Afshin Salsali, Thomas Hach, Hans J Woerle. Diabetes Obes Metab 2016
14
33

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2017
277
33

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Suetonia C Palmer, Dimitris Mavridis, Antonio Nicolucci, David W Johnson, Marcello Tonelli, Jonathan C Craig, Jasjot Maggo, Vanessa Gray, Giorgia De Berardis, Marinella Ruospo,[...]. JAMA 2016
216
33


Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
317
33



Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.
Xiaoyan Zhong, Dan Lai, Yun Ye, Xuping Yang, Bin Yu, Yilan Huang. Eur J Clin Pharmacol 2016
17
25

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
25

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
236
25

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
201
25


Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
369
25


Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
256
25

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
504
25

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
349
25

Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Kyung-Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan-Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong-Sun Kim, Kyong Soo Park, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2018
21
25

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
482
25


Ipragliflozin: first global approval.
Raewyn M Poole, Rosselle T Dungo. Drugs 2014
78
25

Management of type 2 diabetes in adults: summary of updated NICE guidance.
Hugh McGuire, Damien Longson, Amanda Adler, Andrew Farmer, Ian Lewin. BMJ 2016
61
16

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
Katherine Esposito, Paolo Chiodini, Maria Ida Maiorino, Giuseppe Bellastella, Annalisa Capuano, Dario Giugliano. BMJ Open 2014
48
16




Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Michaela Diamant, Michael A Nauck, Rimma Shaginian, James K Malone, Simon Cleall, Matthew Reaney, Danielle de Vries, Byron J Hoogwerf, Leigh MacConell, Bruce H R Wolffenbuttel. Diabetes Care 2014
149
16

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
O J Phung, D M Sobieraj, S S Engel, S N Rajpathak. Diabetes Obes Metab 2014
75
16

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
268
16

The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.
Diana Sherifali, Kara Nerenberg, Eleanor Pullenayegum, Ji Emmy Cheng, Hertzel C Gerstein. Diabetes Care 2010
191
16

Introduction.
. Diabetes Care 2017
266
16



The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.
Dimitris Varvaki Rados, Lana Catani Pinto, Luciana Reck Remonti, Cristiane Bauermann Leitão, Jorge Luiz Gross. PLoS Med 2016
76
16


Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
E S Hong, A R Khang, J W Yoon, S M Kang, S H Choi, K S Park, H C Jang, H Shin, G A Walford, S Lim. Diabetes Obes Metab 2012
63
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.